Nektar Therapeutics NKTR-214 Short Report 2018

Loading viewer...

other

Format: PDF other

Plainview LLC short-seller report from October 2018 arguing that Nektar Therapeutics' NKTR-214 immunotherapy candidate lacks efficacy and misses clinical thresholds. The report claims the drug's mechanism does not achieve stated objectives and compares results unfavorably to competing candidates like epacadostat.

Browse all others →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Nektar Therapeutics

View all →

Nektar Therapeutics 2017 Cowen Healthcare Conference

conference

31 Pages

Nektar Therapeutics 2017 JP Morgan Healthcare Conference

conference

Similar others from other companies

Browse all →

ECN Capital Analyst Update 2017

other

14 Pages

ECN Capital

Alliant International University Catalog 2024-2025

other